Pharmaceuticals News and Research

RSS

Animi-3 may offer hope for rheumatoid arthritis

Animi-3, a prescription medication from PBM Pharmaceuticals, Inc., contains ingredients that may have a beneficial, protective effect in inflammatory diseases such as rheumatoid arthritis (RA).

7 Apr 2005

Florida sues drug company for Medicaid fraud

Charlie Crist, Florida's Attorney General is taking three pharmaceutical companies to court for $25 million, accusing them of illegally inflating prices on generic drugs used to treat depression, schizophrenia, seizures and angina.

6 Apr 2005

Branded drug companies give generics a taste of their own medicine

To defend market share, more branded drug companies today release generic versions of their branded drugs before other generic companies enter the market, according to a study by pharmaceutical intelligence firm, Cutting Edge Information.

6 Apr 2005

Modest triglyceride elevations linked to coronary artery disease risk

Even modest increases in blood levels of triglycerides, as well as a type of high cholesterol known as type III hyperlipidemia, are strongly associated with coronary artery disease in people with a family history of the disease, according to a new study in the April 5, 2005, issue of the Journal of the American College of Cardiology.

5 Apr 2005

Cognitive therapy to treat moderate to severe depression works just as well as antidepressants

The study, conducted by researchers at the University of Pennsylvania and Vanderbilt University, challenges the American Psychiatric Association guidelines that antidepressant medications are the only effective treatment for moderately to severely depressed patients.

5 Apr 2005

Nasal filter new weapon against hay fever

The first clinical trial of a nasal filter has shown that they can significantly reduce both the number of people experiencing symptoms and the severity of their symptoms.

5 Apr 2005

Canadians spend over $21 billion on drugs

Drugs continue to be the fastest-growing category of health care spending in Canada and a new report released by the Canadian Institute for Health Information (CIHI), the Drug Expenditure in Canada 1985-2004 report, shows that total spending on drugs is expected to have reached $21.8 billion in 2004, five times the amount spent on drugs in 1985.

5 Apr 2005

Researchers have identified a new clinical syndrome

Researchers have identified a new clinical syndrome that produces serious and sometimes fatal symptoms in a variety of seemingly unrelated diseases. The syndrome, described in the April 6 issue of the Journal of the American Medical Association, is caused by hemolysis, the destruction of red blood cells.

5 Apr 2005

Metabolic side effects of antipsychotics are known, but rarely monitored

Psychiatrists are doing a “modest” job of monitoring for weight gain, diabetes and other metabolic problems that may result from use of the newer antipsychotics for schizophrenia, researchers say.

5 Apr 2005

Genomics and proteomics to increase the efficiency of drug discovery and development

While the United Sates is still the world leader, Europe is having a good deal of success in the field of advanced genomics and proteomics research. Significant government funding together with the presence of large pharmaceutical companies has made Europe a major competitor in the efforts to deploy genomics and proteomics as vital tools in drug discovery and development.

5 Apr 2005

Natural killer cells could lead to new Hepatitis treatments

Researchers have discovered that natural killer T (NKT) cells, the immune system's sentinels, patrol the labyrinthine blood vessels of the liver for invaders or signs of tissue damage and demonstrate a dogged behavior not seen before in other T cells.

4 Apr 2005

New ion channel drug targets to emerge in pharmaceutical discovery

The identification and structural determination of channel proteins, and their validation as therapeutic targets using high throughput cell based and multiplexed screening technologies, have furnished an increase role for ion channel targets in the drug discovery and development pipelines in the pharmaceutical and biotechnology industries.

4 Apr 2005

Tarvacin shows significant anti-viral activity

Peregrine Pharmaceuticals today announced that there will be two presentations, April 4 and 6, at the American Association of Immunologists (AAI) annual meeting in San Diego, California, indicating the anti-viral potential of its Tarvacin antibody. Dr. Melina Soares of The University of Texas Southwestern Medical Center at Dallas will present pre-clinical data titled "Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever."

4 Apr 2005

Patch therapy provides similar pain relief as oral medications for patients with osteoarthritis (OA) knee pain

Researchers from the Altoona Arthritis and Osteoporosis Center have announced that data presented at the 24th Annual Scientific Meeting of the American Pain Society suggest that patch therapy provides similar pain relief as oral medications for patients with osteoarthritis (OA) knee pain.

3 Apr 2005

New trial for treatment of liver disease

The Nonalcoholic Steatohepatitis (NASH) Clinical Research Network is launching its first two clinical trials for the study of NASH, a liver disease that resembles alcoholic liver disease but occurs in patients who drink little or no alcohol.

3 Apr 2005

Could NAADP/cholecystokinin-combo attack fat from inside and out?

One traditional approach to pharmaceutical design uses so-called “first messengers” – hormones, other natural facilitators or synthetic products – to initiate various cellular cascades for the desired physiological effect. To date, despite concerted efforts at all levels of research, this approach has failed to develop a truly successful obesity drug to address this major global health problem.

3 Apr 2005

Mesoblast moves towards adult stem cell human trials

Exciting Australian adult stem cell company, Mesoblast Limited, today announced that it is set to begin the first human clinical trials using its specialist adult stem cells for orthopaedic and cardiovascular diseases.

30 Mar 2005

AIDS threatens Russian social and economic security

At a meeting this week on the fight with AIDS, Russian Vice-Premier Alexander Zhukov said the AIDS epidemic threatens Russian social and economic security and the spread of the disease is no longer just a medical problem.

30 Mar 2005

New drug to treat chronic hepatitis B

The U.S. Food and Drug Administration (FDA) has given approval for a new drug to treat the potentially life-threatening disease Chronic hepatitis B.

30 Mar 2005

Ranbaxy to appeal injunction against sales of Quinapril

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the U.S. District Court for the District of New Jersey hearing the preliminary injunction motion brought by Pfizer against Teva Pharmaceuticals USA, Inc. (Teva) and Ranbaxy Pharmaceuticals Inc. (RPI) enjoined Teva and RPI from selling RPI's quinapril tablets (5, 10, 20, and 40 mg).

30 Mar 2005